CAJ | 학술논문

乙型肝炎病毒（HBV）感染是全球性的卫生问题，每年有将近100万人死于HBV感染所致的肝衰竭等肝脏疾病。大部分的慢性乙型肝炎（CHB）患者经过抗病毒治疗后可以达到持久的免疫，小部分的还可以达到临床治愈。理想的抗病毒治疗过程一般经过三个重要转折点，分别是 HBV DNA 转阴， HBeAg血清学转换及HBsAg血清学转换。长效干扰素治疗的患者只有40%左右的患者出现HbeAg血清学转化，因此，对CHB患者或许可采取调整患者免疫功能从而达到临床治愈。
을형간염병독（HBV）감염시전구성적위생문제，매년유장근100만인사우HBV감염소치적간쇠갈등간장질병。대부분적만성을형간염（CHB）환자경과항병독치료후가이체도지구적면역，소부분적환가이체도림상치유。이상적항병독치료과정일반경과삼개중요전절점，분별시 HBV DNA 전음， HBeAg혈청학전환급HBsAg혈청학전환。장효간우소치료적환자지유40%좌우적환자출현HbeAg혈청학전화，인차，대CHB환자혹허가채취조정환자면역공능종이체도림상치유。
HBV infection is a global healthy question. Every year almost one million people are dead from HBV related diseases, such as hepatic failure or liver cirrhosis. The majority of the chronic hepatitis B (CHB) patients, who had received antiviral therapy, will get the ability of antiviral persistence immunity while the minority of these patients came up to the standard of clinical cure. The ideal process of antiviral therapy has three important turning points, including HBV DNA seroconversion, HBeAg seroconversion and HBsAg seroconversion. However, only 40%patients who received pegylated interferon therapy have the effect of HBeAg seroconversion. Thus, the CHB patients may achieve clinical cure by regulating their immune functions.